CN105012324A - Composition of kanamycin solubility powder - Google Patents
Composition of kanamycin solubility powder Download PDFInfo
- Publication number
- CN105012324A CN105012324A CN201410174434.3A CN201410174434A CN105012324A CN 105012324 A CN105012324 A CN 105012324A CN 201410174434 A CN201410174434 A CN 201410174434A CN 105012324 A CN105012324 A CN 105012324A
- Authority
- CN
- China
- Prior art keywords
- kanamycin
- soluble powder
- chicken
- group
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to kanamycin solubility powder and a preparation method thereof. The composition of the kanamycin solubility powder is mainly composed of kanamycin mono sulphate, an intestinal absorption enhancer, an intestinal mucosa healing agent, an antioxidant synergist and a metal ion complexing agent. The composition of the kanamycin solubility powder has the effects that water solubility is good, no stimulation to an organism exists, harmful bacteria of the gastrointestinal tract are killed, injured gastrointestinal tract mucosas can be repaired, the immunity of the organism is improved, and the appetite is enhanced.
Description
Technical field
The invention belongs to veterinary drug technical field, particularly relate to and a kind ofly treat medicine of poultry intestinal tract bacteriological infection and preparation method thereof.
Background technology
Intestinal is the multifunction system that poultry body one is very complicated, and it and the other system such as body respiratory system and blood circulation organically combine and play a role.Intestinal can provide some machine-processed especially, and body draws the nutrition needed for poultry growth by these mechanism from intestinal, simultaneously by certain protective mechanism protection host.Intestinal itself can be used as the living environment of many pathogenic microorganisms in addition.The feed environment of poultry and the health of feedstuff extremely important, but along with the develop rapidly of aquaculture, very easily there is the intestinal infection case of fowl, and can infect rapidly along with feces, after poultry is ill, food-intake declines, body weight reduces, as treated not in time, mortality rate is high, causes the economic loss of raiser.
At present, the most effect of medicine being used for the treatment of intestinal infection disease in domestic veterinary drug market significantly or later stage relapse rate higher, mainly because bacterial drug resistance is comparatively strong, oxidation of drug, medicine molten water time tap water in the impact of metal ion, intestinal injury seriously cause absorbing the reasons such as not good.
According to Clinical practice and pathogeneticing characteristic, the present invention selects kanamycin sulfate, by adding short intestinal absorption agent, wraps up medicine, and the polarity of medicine is reduced, and promotes that medicine better absorbs; Glutamine is body essential amino acids, is also simultaneously the energy substance of intestinal mucosa, for the synthesis of purine and protein provides nitrogenous source donor, provides DNA replication dna and cell division institute's energy requirement and nucleotide base; Glutamine can promote the function such as growth, reparation of intestinal villus simultaneously; Metal ion can accelerate the oxidation of medicine, thus drug effect is reduced, disodium edetate can with metal ion-chelant, reduce the oxygenation efficiency of medicine, improve the curative effect of product.
Summary of the invention
The object of the invention is to provide a kind of kanamycin soluble powder, drinks water and takes, kill harmful intestinal tract bacteria when birds generation digestive tract disease, and to impaired cell migration, increases appetite, supplements the nutrients, improves immunity of organisms.The present invention is achieved through the following technical solutions:
A kind of kanamycin soluble powder, raw material of the present invention consists of Kanamicina Solfato 10 ~ 15%, intestinal absorption enhancers 3-6%, glutamine 0.7 ~ 0.9%, antioxidant 0.025-0.06%, disodium edetate 0.03-0.05%, anhydrous glucose add to 100%.
The raw material of described soluble powder consists of Kanamicina Solfato 11%, intestinal absorption enhancers 3%, glutamine 0.7%, antioxidant 0.025%, disodium edetate 0.03%, anhydrous glucose add to 100%.
The raw material of described soluble powder consists of Kanamicina Solfato 12%, intestinal absorption enhancers 4.5%, glutamine 0.8%, antioxidant 0.04%, disodium edetate 0.045%, anhydrous glucose add to 100%.
The raw material of described soluble powder consists of Kanamicina Solfato 15%, intestinal absorption enhancers 6%, glutamine 0.9%, antioxidant 0.06%, disodium edetate 0.05%, anhydrous glucose add to 100%.
Described short intestinal absorption agent is cyclodextrin, chitosan, salicylic one or several.
Described antioxidant be sodium sulfite, sodium metabisulfite, sodium bisulfate one or several
In order to obtain better effect, preferred prescription is: Kanamicina Solfato 12%, intestinal absorption enhancers 4.5%, glutamine 0.8%, antioxidant 0.04%, disodium edetate 0.045%, anhydrous glucose add to 100%.
Kanamycin in this compositions is aminoglycoside medicaments, comprises escherichia coli, Pseudomonas aeruginosa, Enterobacter, Klebsiella etc. have powerful antibacterial activity to various aerobic gram negative bacteria; First the agent of intestinal penetration enhancement by wrapping up medicine, penetration enhancement agent with positive charge group can with electronegative serine Interaction of substituents in cell membrane protein, reversibly open compact siro spinning technology and increase paracellular transport, promoting that medicine is in intestinal absorption; Glutamine makes impairedly gastrointestinal tract mucously to be able to rapid reparation; Antioxidant and metal ion chelation agent by suppressing the metal ion in the oxidation of medicine and chelating tap water, thus play the effect of medicine.
Detailed description of the invention
By clinical trial, clinical effectiveness of the present invention is described:
Embodiment 1
Clinical trial one
(1) experimental animal
Tianjin chicken house has a collection of 18 Day-old Broiler Chickens, and find that chicken spirit is depressed, feed intake declines, and cuing open the visible abdominal cavity of inspection has yellow fibers element film to cover, and liver, heart enlargement, gastrointestinal mucosal is hemorrhage, and gastrointestinal tract mucous have ulcer.
(2) test drug: the embodiment of the present invention 2 prepared medicines.
(3) EXPERIMENTAL DESIGN and method
The sick chicken 280 of this chicken house of Stochastic choice, test group 1 is routine administration group, selects commercially available kanamycin soluble powder (specification 12%), mixed drink, every 1L water, and 1.0g, is used in conjunction three days; Test group 2 is the embodiment of the present invention 2 medicine group, and mixed drink, every 1L water, 1.2g, is used in conjunction three days.
(4) curative effect determinate standard
Cure rate: after off-test, spirit, appetite, clinical symptoms recover the ratio that normal sick chicken accounts for the total chicken number of this group completely.
Effective percentage: after off-test spirit, appetite, clinical symptoms be clearly better sick chicken account for the ratio of the total chicken number of this group.
Inefficiency: duration of test occurs dead, and the sick chicken of not feeling any better after medication accounts for the ratio of the total chicken number of this group.
Table 1 medicine of the present invention divides into groups to fowl digestive tract disease controlling experiment
(5) result of the test
Medicine of the present invention is to the curative effect of poultry.
Table 2 clinical test results
Experimental group 2 chicken group is after taking the embodiment of the present invention 2 medicine, and the chicken group mental status is clearly better, and feed intake obviously increases.
Clinical trial two
(1) experimental animal
Guangdong chicken house has the yellow chickens of a collection of 40 ages in days, and find that chicken spirit is depressed, appetite declines, and flocks together and dozes off, and cuing open crisp, the indivedual liver of the visible liver enlargement matter of inspection has the downright bad point of canescence, digestive tract mucosal hyperaemia, hemorrhage.
(2) test drug: the embodiment of the present invention 3 prepared medicines.
(3) EXPERIMENTAL DESIGN and method
The sick chicken 300 of this chicken house of Stochastic choice, test group 1 is routine administration group, selects commercially available kanamycin soluble powder (specification 12%), mixed drink, every 1L water, and 1.0g, is used in conjunction three days; Test group 2 is prepared medicines by the embodiment of the present invention 3.Medicine group of the present invention, mixed drink, every 1L water, 1.0g, is used in conjunction three days.
(4) curative effect determinate standard
Cure rate: after off-test, spirit, appetite, clinical symptoms recover the ratio that normal sick chicken accounts for the total chicken number of this group completely.
Effective percentage: after off-test spirit, appetite, clinical symptoms be clearly better sick chicken account for the ratio of the total chicken number of this group.
Inefficiency: duration of test occurs dead, and the sick chicken of not feeling any better after medication accounts for the ratio of the total chicken number of this group.
Table 3 medicine of the present invention divides into groups to fowl digestive tract disease controlling experiment
(5) result of the test
Medicine of the present invention is to the curative effect of poultry.
Table 4 clinical test results
Experimental group 2 chicken group is after taking the embodiment of the present invention 3 medicine, and the chicken group mental status is clearly better, and mortality rate declines, and feed intake obviously increases.
Clinical trial three
(1) experimental animal
Shandong chicken house has a collection of 4 Day-old Broiler Chickens, and find that chicken spirit is tired, drop-head, abdominal part enlargement, feed intake declines, and arranges white watery stools, and cut open inspection visible abdominal cavity absorption of yolk at its bad, liver, heart enlargement, gastrointestinal mucosal is thinning, has congested hemorrhage.
(2) test drug: the embodiment of the present invention 4 prepared medicines.
(3) EXPERIMENTAL DESIGN and method
The sick chicken 1000 of this chicken house of Stochastic choice, test group 1 is routine administration group, selects commercially available kanamycin soluble powder (specification 12%), mixed drink, every 1L water, and 1.0g, is used in conjunction three days; Test group 2 is the embodiment of the present invention 4 medicine group, and mixed drink, every 1L water, 0.8g, is used in conjunction three days.
(4) curative effect determinate standard
Cure rate: after off-test, spirit, appetite, clinical symptoms recover the ratio that normal sick chicken accounts for the total chicken number of this group completely.
Effective percentage: after off-test spirit, appetite, clinical symptoms be clearly better sick chicken account for the ratio of the total chicken number of this group.
Inefficiency: duration of test occurs dead, and the sick chicken of not feeling any better after medication accounts for the ratio of the total chicken number of this group.
Table 5 medicine of the present invention divides into groups to fowl digestive tract disease controlling experiment
(5) result of the test
Medicine of the present invention is to the curative effect of poultry.
Table 6 clinical test results
Experimental group 2 chicken group is after taking the embodiment of the present invention 4 medicine, and the chicken group mental status is clearly better, and feed intake obviously increases.
Can observe beneficial effect of the present invention with the following Examples, these embodiments are illustrative, can not be construed as limiting the present invention.
Embodiment 2
Preparation method:
1, get anhydrous glucose to pulverize, cross 80 mesh sieves;
2, first get Kanamicina Solfato to mix homogeneously with chitosan, then dilute four times with sodium sulfite, disodium edetate and the anhydrous glucose equivalent dilution method that progressively increases, cross 60 order fine screens, obtain the uniform mixture of a kind of elementary mixing.
3, get said mixture to mix with glutamine sugar, cross 60 order fine screens, obtain the uniform mixture of a kind of elementary mixing.
4, said mixture and remaining anhydrous glucose add in mixer, mix 30 minutes, to obtain final product.
Embodiment 3
1, get anhydrous glucose to pulverize, cross 80 mesh sieves;
2, first get Kanamicina Solfato to mix homogeneously with chitosan, then dilute four times with sodium sulfite, disodium edetate and the anhydrous glucose equivalent dilution method that progressively increases, cross 60 order fine screens, obtain the uniform mixture of a kind of elementary mixing.
3, get said mixture to mix with glutamine sugar, cross 60 order fine screens, obtain the uniform mixture of a kind of elementary mixing.
4, said mixture and remaining anhydrous glucose add in mixer, mix 30 minutes, to obtain final product.
Embodiment 4
Preparation method:
1, get anhydrous glucose to pulverize, cross 80 mesh sieves;
2, first get Kanamicina Solfato to mix homogeneously with chitosan, then dilute four times with sodium sulfite, disodium edetate and the anhydrous glucose equivalent dilution method that progressively increases, cross 60 order fine screens, obtain the uniform mixture of a kind of elementary mixing.
3, get said mixture to mix with glutamine sugar, cross 60 order fine screens, obtain the uniform mixture of a kind of elementary mixing.4, said mixture and remaining anhydrous glucose add in mixer, mix 30 minutes, to obtain final product.
Claims (6)
1. the prescription of a kanamycin soluble powder, it is characterized in that, the raw material of described soluble powder consists of Kanamicina Solfato 10 ~ 15%, intestinal absorption enhancers 3-6%, glutamine 0.7 ~ 0.9%, antioxidant 0.025-0.06%, disodium edetate 0.03-0.05%, anhydrous glucose add to 100%.
2. the prescription of a kind of kanamycin soluble powder according to claim 1, it is characterized in that, the raw material of this soluble powder consists of Kanamicina Solfato 10%, intestinal absorption enhancers 3%, glutamine 0.7%, antioxidant 0.025%, disodium edetate 0.03%, anhydrous glucose add to 100%.
3. the prescription of a kind of kanamycin soluble powder according to claim 1, it is characterized in that, the raw material of this soluble powder consists of Kanamicina Solfato 12%, intestinal absorption enhancers 4.5%, glutamine 0.8%, antioxidant 0.04%, disodium edetate 0.045%, anhydrous glucose add to 100%.
4. the prescription of a kind of kanamycin soluble powder according to claim 1, it is characterized in that, the raw material of this soluble powder consists of Kanamicina Solfato 15%, intestinal absorption enhancers 6%, glutamine 0.9%, antioxidant 0.06%, disodium edetate 0.05%, anhydrous glucose add to 100%.
5. according to the prescription of the arbitrary described a kind of kanamycin soluble powder of claim 1-4, it is characterized in that, described short intestinal absorption agent is cyclodextrin, chitosan, one or more combinations salicylic.
6. according to the prescription of the arbitrary described a kind of kanamycin soluble powder of claim 1-4, it is characterized in that, described antioxidant is one or more combinations of sodium sulfite, sodium metabisulfite, sodium bisulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410174434.3A CN105012324A (en) | 2014-04-28 | 2014-04-28 | Composition of kanamycin solubility powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410174434.3A CN105012324A (en) | 2014-04-28 | 2014-04-28 | Composition of kanamycin solubility powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105012324A true CN105012324A (en) | 2015-11-04 |
Family
ID=54402873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410174434.3A Pending CN105012324A (en) | 2014-04-28 | 2014-04-28 | Composition of kanamycin solubility powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105012324A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344265A (en) * | 2020-10-14 | 2022-04-15 | 洛阳瑞华动物保健品有限公司 | Preparation method of kanamycin monosulfate soluble powder |
-
2014
- 2014-04-28 CN CN201410174434.3A patent/CN105012324A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344265A (en) * | 2020-10-14 | 2022-04-15 | 洛阳瑞华动物保健品有限公司 | Preparation method of kanamycin monosulfate soluble powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2224918T3 (en) | The use of EDTA and its salts for the prevention and treatment of bacterial intestinal diseases of pigs | |
| Xie et al. | Enteromorpha polysaccharide-zinc replacing prophylactic antibiotics contributes to improving gut health of weaned piglets | |
| KR101803069B1 (en) | Composition for improving livestock immunity comprising probiotics as effective component | |
| Andronikashvili et al. | Possibility of application of natural zeolites for medicinal purposes | |
| JP2024501786A (en) | Antimicrobial composition, its manufacturing method, and its products | |
| CN103006820A (en) | Chinese medicinal composition with functions of clearing heat and drying dampness and preparation method thereof | |
| ES2817623T3 (en) | Food supplement additive | |
| CN105012324A (en) | Composition of kanamycin solubility powder | |
| CN101269164B (en) | Method of preparing virus bacterium blood serum Chinese aloe vaccine powder preparation and oral liquid for livestock, poultry biology and aquatic animal | |
| KR20090040268A (en) | Pathogenic attenuation via the administration of an equilibiotic compound | |
| CN107823325A (en) | Fish germ inhibitor | |
| CN106666150A (en) | Nonreactive health-care agent capable of improving production performance of breeding pigs and preparation method of nonreactive health-care agent | |
| RU2629814C1 (en) | Preparation for treatment of gastrointestinal diseases of calves protecting with diarrhea signs | |
| CN102488767B (en) | Compound composition for treating bacterial diarrhoea of livestock and poultry | |
| CN109464653A (en) | A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof | |
| CN102688477A (en) | Medicinal composition for treating respiratory diseases of livestock | |
| RU2415675C2 (en) | Method of prevention of gastrointestinal diseases in shoats | |
| CN110179758B (en) | Crystalline valnemulin hydrochloride soluble powder capable of being administered by drinking water and application thereof | |
| RU2366431C2 (en) | Method for preparing disintoxicant for animals | |
| RU2381796C2 (en) | Preparation "diaron" for treatment of acute gastrointestinal diseases of newborn calves | |
| CN106138184A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae and amoxicillin | |
| JP2002020297A (en) | Oral adsorption carbon preparation | |
| CN114344265A (en) | Preparation method of kanamycin monosulfate soluble powder | |
| CN104645311A (en) | Drinking agent for treating intestinal infection of livestock and poultry and preparation method of drinking agent | |
| CN103918910A (en) | Chicken feed with effect of preventing fowl plague |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151104 |
|
| WD01 | Invention patent application deemed withdrawn after publication |